Drug therapy in attention-deficit hyperactivity disorder.
Of 292 patients (210 males and 82 females) receiving medication for attention-deficit hyperactivity disorder (ADHD), 272 (93%) responded well to sustained-release dextroamphetamine (D-Amp) and 21 patients (7%) to sustained-release methylphenidate (MPD). The dose of D-Amp ranged from 0.2 to 3.6 mg/kg/day and the dose of MPD from 1.4 to 7.7 mg/kg/day, without side effects requiring cessation of therapy. This suggests that the clinical improvement rate can be increased to nearly 100% in appropriate situations.
Kessler
S
S
D000293:Adolescent; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D002491:Central Nervous System Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003692:Delayed-Action Preparations; D003913:Dextroamphetamine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007361:Intelligence Tests; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage*
D002491:Central Nervous System Agents; D003692:Delayed-Action Preparations; D008774:Methylphenidate; D003913:Dextroamphetamine